Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism
International Journal of Endocrinology · 2026-01 · 2026 (1)
DOI: 10.1155/ije/6930716 ↗Abstract
Purpose To evaluate short‐term changes in serum calcium and the occurrence of values below prespecified thresholds after denosumab treatment in institutional oncology and primary hyperparathyroidism (PHPT) cohorts, and to interpret these findings within the context of FAERS reporting patterns and published PHPT evidence. Methods We retrospectively analysed denosumab‐treated patients at the Affiliated Hospital of Inner Mongolia Medical University; the retrospective study was performed in the Department of Clinical Pharmacy (oncology cohort, 2024; PHPT cohort, 2022–April 2025). Total serum calcium was evaluated at baseline and around Days 3 and 7. A downstream FAERS reanalysis used the fixed 2014Q1–2023Q2 dataset, and published PHPT reports were re‐extracted for actual follow‐up and complications. Results In the oncology subgroup with baseline calcium > 2.55 mmol/L, mean paired calcium changed from 3.101 to 2.278 mmol/L at Day 3 ( n = 12; p = 0.0002) and from 3.158 to 1.990 mmol/L at Day 7 ( n = 11; p < 0.0001). In PHPT, the corresponding changes were 3.376 to 2.661 mmol/L at Day 3 ( n = 9; p = 0.0038) and 3.351 to 2.289 mmol/L at Day 7 ( n = 8; p = 0.0013). During Days 1–10, calcium < 2.10 mmol/L occurred in 57/102 oncology patients with non‐low baseline calcium and 4/9 PHPT patients; values < 1.60 mmol/L occurred in 3/102 and 0/9, respectively. Among 1433 FAERS hypocalcaemia reports, 1186 (82.76%) had at least one serious‐outcome code, most often hospitalisation/prolonged hospitalisation (769; 53.66%) or another medically important condition (725; 50.59%). Crude hypocalcaemia reporting proportions were higher for 120 mg than 60 mg, for male than female reports, and for tumour‐related than osteoporosis indications; the youngest evaluable age strata also had higher proportions, but denominators were small, and the comparisons were unadjusted. Conclusion In the analysed cohorts, denosumab was followed by short‐term calcium reduction in patients with baseline hypercalcaemia and in the small PHPT cohort. Values below 2.10 mmol/L were common in early follow‐up, whereas values below 1.60 mmol/L were uncommon, and clinical hypocalcaemia was not systematically adjudicated. FAERS hypocalcaemia reports often carried serious‐outcome codes, mainly hospitalisation and other medically important conditions, without establishing incidence, causality or independent risk factors.
EUVIMED